文献速递脑血管病

恩格列净与高心血管风险2型糖尿病患者脑血管事件

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
PubMed 文献 · Stroke · 2017-04-06

EMPA-REG OUTCOME试验将7020例高心血管风险2型糖尿病患者随机分配至恩格列净10mg、25mg或安慰剂组,中位观察3.1年。改良意向治疗分析中卒中风险比为1.18(95%CI 0.89-1.56;P=0.26),基于治疗期间或末次给药后≤90天内事件的敏感性分析中卒中风险比为1.08(95%CI 0.81-1.45;P=0.60)。结论为恩格列净与安慰剂相比脑血管事件风险无显著差异。

要点

  • 恩格列净组与安慰剂组卒中风险无显著差异,敏感性分析风险比1.08。
  • 复发、致死、致残性卒中及短暂性脑缺血发作风险均无差异。
  • 血细胞比容升高或收缩压下降幅度最大的患者未增加卒中风险。

核心结论

  • 在高心血管风险2型糖尿病患者中,恩格列净与安慰剂相比脑血管事件风险无显著差异。

研究设计与样本

  • EMPA-REG OUTCOME试验将患者随机分配至恩格列净10mg、恩格列净25mg或安慰剂组。
  • 共7020例患者接受治疗,中位观察时间3.1年。
  • 分析包括改良意向治疗分析和基于治疗期间或末次给药后≤90天内事件的敏感性分析。

主要发现

  • 改良意向治疗分析中,恩格列净组卒中风险比为1.18(95%CI 0.89-1.56;P=0.26)。
  • 敏感性分析中,恩格列净组卒中风险比为1.08(95%CI 0.81-1.45;P=0.60)。
  • 改良意向治疗分析的数值差异主要源于恩格列净组18例患者末次给药后>90天发生首次事件(安慰剂组3例)。
  • 恩格列净与安慰剂相比,复发、致死、致残性卒中及短暂性脑缺血发作风险无差异。
  • 血细胞比容升高或收缩压下降幅度最大的患者未增加卒中风险。

临床怎么用

  • 对于高心血管风险2型糖尿病患者,恩格列净治疗不增加脑血管事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), empagliflozin added to standard of care in patients with type 2 diabetes mellitus and high cardiovascular risk reduced the risk of 3-point major adverse cardiovascular events, driven by a reduction in cardiovascular mortality, with no significant difference between empagliflozin and placebo in risk of myocardial infarction or stroke. In a modified intent-to-treat analysis, the hazard ratio for stroke was 1.18 (95% confidence interval, 0.89-1.56; P=0.26). We further investigated cerebrovascular events. METHODS: Patients were randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo; 7020 patients were treated. Median observation time was 3.1 years. RESULTS: The numeric difference in stroke between empagliflozin and placebo in the modified intent-to-treat analysis was primarily because of 18 patients in the empagliflozin group with a first event >90 days after last intake of study drug (versus 3 on placebo). In a sensitivity analysis based on events during treatment or ≤90 days after last dose of drug, the hazard ratio for stroke with empagliflozin versus placebo was 1.08 (95% confidence interval, 0.81-1.45; P=0.60). There were no differences in risk of recurrent, fatal, or disabling strokes, or transient ischemic attack, with empagliflozin versus placebo. Patients with the largest increases in hematocrit or largest decreases in systolic blood pressure did not have an increased risk of stroke. CONCLUSIONS: In patients with type 2 diabetes mellitus and high cardiovascular risk, there was no significant difference in the risk of cerebrovascular events with empagliflozin versus placebo. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01131676.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zinman B, Inzucchi SE, Lachin JM, et al. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke. 2017. PMID: 28386035. doi:10.1161/STROKEAHA.116.015756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。